Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Dagar, Gunjan; Gupta, Ashna; Masoodi, Tariq; Nisar, Sabah; Merhi, Maysaloun; Hashem, Sheema; Chauhan, Ravi; Dagar, Manisha; Mirza, Sameer; Bagga, Puneet; Kumar, Rakesh; Akil, Ammira S. Al-Shabeeb; Macha, Muzafar A.; Haris, Mohammad; Uddin, Shahab; Singh, Mayank; Bhat, Ajaz A.

doi:10.1186/s12967-023-04292-3

Table 2 Major ongoing clinical trials of CAR-T cell therapy in different cancers

From: Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Condition	Intervention	Phase	Clinical trial identifier	Estimated completion date	Sponsors/site	Status	Source
Breast cancer	CEA	Phase I/II	NCT04348643	April 30, 2023	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Multi-4SCAR T	Phase I/II	NCT04430595	December 31, 2023	Shenzhen Geno-Immune Medical Institute	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Multi-4SCAR T	Phase I/II	NCT04430595	December 31, 2023	The Seventh Affiliated Hospital of Sun Yat-sen University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-hCD70	Phase I/II	NCT02830724	January 1, 2028	National Cancer Institute (NCI)	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	cMET RNA	Phase I	NCT01837602	August 13, 2018 (Completed)	University of Pennsylvania	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	huMNC2-CAR44	Phase I	NCT04020575	January 15, 2035	Minerva Biotechnologies Corporation	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	huMNC2-CAR44	Phase I	NCT04020575	January 15, 2035	City of Hope Medical Centre	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	EGFR/B7H3	Early Phase I	NCT05341492	May 1, 2025	Second Affiliated Hospital of Guangzhou Medical University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	HER2-BPX-603	Phase I/II	NCT04650451	January 2, 2027	Bellicum Pharmaceuticals	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-CD133	Phase I/II	NCT02541370	June 2019	Chinese PLA General Hospital	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Multiple myeloma	CD138	Phase I/II	NCT01886976	June 2016	Chinese PLA General Hospital	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	BCMA	Early Phase I	NCT05430945	June 20, 2025	Zhejiang University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	BCMA	Early Phase I	NCT05430945	June 20, 2025	Yake Biotechnology Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CS1	Early Phase I	NCT04541368	December 31, 2026	Zhejiang University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CS1	Early Phase I	NCT04541368	December 31, 2026	Yake Biotechnology Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	BCMA	Phase I/II	NCT04271644	July 1, 2023	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	ALLO-715	Phase I	NCT04093596	December 2027	Allogene Therapeutics	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-CD19/BCMA	Phase I	NCT03706547	December 2021	Peng Liu	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Hrain Biotechnology
					Shanghai East Hospital
	Anti-BCMA/GPRC5D	Phase II	NCT05509530	May 1, 2025	Xuzhou Medical University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	BCMA	Phase I/II	NCT03548207	August 23, 2022	Janssen Research and Development, LLC	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	BCMA	Phase I	NCT04706936	April 2024	Second Affiliated Hospital, School of Medicine, Zhejiang University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Carbiogene Therapeutics Co. Ltd
	CS1 (UCART)	Phase I	NCT04142619	December 11, 2024	Cellectis S.A	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Glioblastoma	CD147	Phase I	NCT04045847	May 30, 2022	Xijing Hospital		Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	IL13Rα2	Phase I	NCT04003649	December 1, 2022	City of Hope Medical Center		Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					National Cancer Institute (NCI)
	EphA2	Phase I	NCT03423992	January 30, 2023	Xuanwu Hospital, Beijing	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Beijing Mario Biotech Company
					Hebei Senlang BIotech Company
					Beijing HuiNengAn Biotech Company
	EGFRvIII	Phase I	NCT03283631	June 30, 2020	Gary Archer Ph.D.	Terminated	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					National Cancer Institute (NCI)
					Duke Cancer Institute
	MPP2 +	Phase I	NCT04214392	February 6, 2023	City of Hope Medical Center	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	MPP2 +	Phase I	NCT04214392	February 6, 2023	National Cancer Institute (NCI)	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	B7-H3	Phase I	NCT05241392	December 31, 2024	Beijing Tiantan Hospital	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	HER	Phase I	NCT01109095	March 7, 2018	Baylor College of Medicine	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					The Methodist Hospital Research Institute
					Center for Cell and Gene Therapy, Baylor College of Medicine
	GD-2	Phase I	NCT00085930	June 2023	Baylor College of Medicine	Active, not Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	GD-2	Phase I	NCT00085930	June 2023	Center for Cell and Gene Therapy, Baylor College of Medicine	Active, not Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Ovarian Cancer	CD133	Phase I/II	NCT02541370	June 2019	Chinese PLA General Hospital	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-ALPP	Phase I/II	NCT04627740	December 31, 2023	Xinqiao Hospital of Chongqing	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-MESO	Phase I	NCT03814447	January 2023	Shanghai 6th People's Hospital	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-MESO	Phase I	NCT03814447	January 2023	Hrain Biotechnology Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CD70	Phase I	NCT05518253	May 30, 2025	Weijia Fang, MD	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CD70	Phase I	NCT05518253	May 30, 2025	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	TAG72	Phase I	NCT05225363	November 5, 2026	City of Hope Medical Center	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	TAG72	Phase I	NCT05225363	November 5, 2026	National Cancer Institute (NCI)	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	fhB7H3	Phase I/II	NCT05211557	August 31, 2026	The Affiliated Hospital of Xuzhou Medical University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Xuzhou Medical University
					IIT MediTech (Jiangsu) Co. Ltd
	αPD1-MSLN	Early Phase I	NCT04503980	June 2022	Shanghai Cell Therapy Group Co., Ltd	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	αPD1-MSLN	Early Phase I	NCT04503980	June 2022	Shanghai 10th People's Hospital	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CLDN 18.2	Phase I	NCT05472857	December 2024	Suzhou Immunofoco Biotechnology Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CLDN 18.2	Phase I	NCT05472857	December 2024	Changhai Hospital	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Lung Cancer	αPD1-MSLN	Early Phase I	NCT04489862	December 2022	Wuhan Union Hospital, China	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	αPD1-MSLN	Early Phase I	NCT04489862	December 2022	Shanghai Cell Therapy Group Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-MUC1	Phase I/II	NCT03525782	January 31, 2022	The First Affiliated Hospital of Guangdong Pharmaceutical University	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Guangzhou Anjie Biomedical Technology Co., Ltd
					University of Technology, Sydney
	TAA06	Phase I	NCT05190185	December 1, 2023	PersonGen BioTherapeutics (Suzhou) Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	TAA06	Phase I	NCT05190185	December 1, 2023	Department of Immunology, The Fourth Hospital of Hebei Medical University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CEA	Phase I/II	NCT04348643	April 30, 2023	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	P-MUC1C-ALLO1	Phase I	NCT05239143	April 2039	Poseida Therapeutics, Inc.	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	EGFR/B7H3	Early Phase I	NCT05341492	May 1, 2025	Second Affiliated Hospital of Guangzhou Medical University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CAdVEC and HER2	Phase I	NCT03740256	December 30, 2038	Baylor College of Medicine	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					The Methodist Hospital Research Institute
	CEA	Phase I/II	NCT04348643	April 30, 2023	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Prostate Cancer	EpCAM	Phase I/II	NCT03013712	December 2020	First Affiliated Hospital of Chengdu Medical College	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	P-PSMA-101	Phase I	NCT04249947	September 2036	Poseida Therapeutics, Inc.	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t	Phase I	NCT03873805	December 31, 2023	City of Hope Medical Center	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					National Cancer Institute (NCI)
	PD1-PSMA	Phase I	NCT04768608	January 2024	Zhejiang University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Bioray Laboratories
	BPX-601	Phase I/II	NCT02744287	February 2026	Bellicum Pharmaceuticals	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Liver Cancer	Anti-CEA	Phase I	NCT05240950	December 25, 2026	Changhai Hospital	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	IM83	Phase I	NCT05123209	August 30, 2023	Beijing Immunochina Medical Science & Technology Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	GPC3	Phase I	NCT05344664	February 1, 2025	Peking University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-CD133	Phase I/II	NCT02541370	June 2019	Chinese PLA General Hospital	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	IL15 (AGAR)	Phase I	NCT04377932	February 1, 2040	Baylor College of Medicine	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Center for Cell and Gene Therapy, Baylor College of Medicine
	HerinCAR-PD1	Phase I/II	NCT02862028	July 2018	Shanghai International Medical Center	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-CEA	Early Phase I	NCT04513431	August 30, 2023	Ruijin Hospital	Not yet Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					HuaDao (Shanghai) Biomedical Co., Ltd
Pancreatic Cancer	CT041	Phase I/II	NCT04404595	September 1, 2035	CARsgen Therapeutics Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	HEC-016	Early Phase I	NCT05277987	March 2025	Shenzhen Fifth People's Hospital	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	IM96	Early Phase I	NCT05287165	June 30, 2024	Beijing Immunochina Medical Science & Technology Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	TAI-meso	Phase I	NCT02706782	September 2018	Shanghai GeneChem Co., Ltd	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Claudin 18.2	Phase I	NCT05472857	December 2024	Suzhou Immunofoco Biotechnology Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Changhai Hospital
	KD-496	Early Phase I	NCT05583201	June 1, 2026	Jianming Xu	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					KAEDI
	CT041	Phase I/II	NCT04581473	June 30, 2038	CARsgen Therapeutics Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Peking University Cancer Hospital & Institute
					Fudan University
	Anti-hCD70	Phase I/II	NCT02830724	January 1, 2028	National Cancer Institute (NCI)	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
Colorectal Cancer	NKG2D	Early Phase I	NCT05248048	October 2022	The Third Affiliated Hospital of Guangzhou Medical University	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Hangzhou Cheetah Cell Therapeutics Co., Ltd
	Anti-CEA	Phase I	NCT05240950	December 25, 2026	Changhai Hospital	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	αPD1-MSLN	Early Phase I	NCT04503980	June 2022	Shanghai Cell Therapy Group Co., Ltd	Unknown	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
					Shanghai 10th People's Hospital
	CEA	Phase I/II	NCT04348643	April 30, 2023	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	CEA	Phase I	NCT05415475	September 15, 2024	Chongqing Precision Biotech Co., Ltd	Recruiting	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-CD133	Phase I/II	NCT02541370	June 2019	Chinese PLA General Hospital	Completed	Clinicaltrials.gov, NIH, U.S. National Library of Medicine
	Anti-HER2	Phase I/II	NCT02713984	July 2019	Zhi Yang	Withdrawn	Clinicaltrials.gov, NIH, U.S. National Library of Medicine

Back to article page

ISSN: 1479-5876

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com

Journal of Translational Medicine

Contact us